Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4470466 | 0.80 | — | — | |
| SCHEMBL4472621 | 0.68 | ALOX5 (0.34) | — | |
| SCHEMBL5267649 | 0.66 | ALDH1A1 (0.44) | KDM4EALDH1A1MAPT | |
| SCHEMBL27765966 | 0.61 | PTGS1 (0.55) | ALDH1A1 | |
| SCHEMBL4481625 | 0.60 | KDM4E (0.37) | KDM4EALDH1A1 | |
| SCHEMBL10339401 | 0.60 | KMT2A (0.31) | ALDH1A1 | |
| Durohydroquinone SCHEMBL69786 | 0.56 | ALOX5 (0.38) | ALDH1A1 | |
| SCHEMBL933085 | 0.55 | PTGS1 (0.38) | — | |
| SCHEMBL20322375 | 0.54 | — | — | |
| SCHEMBL2527849 | 0.54 | SENP1 (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856040-A2 | NOVEL LIPOXYGENASE INHIBITORS | Eli Lilly and Company (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006093547-A2 | NOVEL LIPOXYGENASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060193797-A1 | Chroman derivatives as lipoxygenase inhibitors | GALILEO PHARMACEUTICALS, INC | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060193797-A1 | Chroman derivatives as lipoxygenase inhibitors | NR0B1, ALOX5, ALOX15B | KDM4E 2240/4885ALDH1A1 757/4885MAPT 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.